Pancreatic Cancer Research

ResearcherUniversity of VeronaActive in the last 2 years

Laura Maggino

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-6248-4480; OpenAlex author ID A5009250320. Sources: OpenAlex.

Their work

Papers
31 (first author 7, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
186
Papers, trials and grants by year

2016: 1 paper · 2017: 3 papers · 2018: 4 papers · 2019: 3 papers · 2020: 7 papers · 2021: none · 2022: 3 papers · 2023: 7 papers · 2024: 1 paper · 2025: 1 paper · 2026: 1 paper

Papers 31

  1. Upfront surgery vs. neoadjuvant therapy in pancreatic cancer with venous involvement: a multicenter retrospective analysis. Co-author DOI 10.1007/s00423-026-04291-0↗
  2. Purely resectable versus biological borderline resectable pancreatic cancer: closely related or worlds apart? Co-author DOI 10.1093/bjsopen/zraf054↗
  3. The Difficulty of Detecting Occult Metastases in Patients with Potentially Resectable Pancreatic Cancer: Development and External Validation of a Preoperative … First author DOI 10.3390/jcm13061679↗
  4. Clinical and Genomic Characterization of Pancreatic Ductal Adenocarcinoma with Signet-Ring/Poorly Cohesive Cells. Co-author DOI 10.1016/j.modpat.2023.100251↗
  5. A dynamic analysis of empirical survival outcomes after pancreatectomy for pancreatic ductal adenocarcinoma. First author DOI 10.1016/j.surg.2022.11.015↗
  6. Pathological staging in postneoadjuvant pancreatectomy for pancreatic cancer: implications for adjuvant therapy. Co-author DOI 10.1093/bjs/znad146↗
  7. CA19.9 Response and Tumor Size Predict Recurrence Following Post-neoadjuvant Pancreatectomy in Initially Resectable and Borderline Resectable Pancreatic Ductal… Co-author DOI 10.1245/s10434-022-12622-w↗
  8. FOLFIRINOX or Gemcitabine-based Chemotherapy for Borderline Resectable and Locally Advanced Pancreatic Cancer: A Multi-institutional, Patient-Level, Meta-analy… Co-author DOI 10.1245/s10434-023-13353-2↗
  9. Body composition parameters, immunonutritional indexes, and surgical outcome of pancreatic cancer patients resected after neoadjuvant therapy: A retrospective,… Co-author DOI 10.3389/fnut.2023.1065294↗
  10. Corrigendum: Body composition parameters, immunonutritional indexes, and surgical outcome of pancreatic cancer patients resected after neoadjuvant therapy: a r… Co-author DOI 10.3389/fnut.2023.1212436↗
  11. Reassessment of the Optimal Number of Examined Lymph Nodes in Pancreatoduodenectomy for Pancreatic Ductal Adenocarcinoma. First author DOI 10.1097/sla.0000000000004552↗
  12. A Pretreatment Prognostic Score to Stratify Survival in Pancreatic Cancer. Co-author DOI 10.1097/sla.0000000000004845↗
  13. Importance of Nodal Metastases Location in Pancreatoduodenectomy for Pancreatic Ductal Adenocarcinoma: Results from a Prospective, Lymphadenectomy Protocol. First author DOI 10.1245/s10434-022-11417-3↗
  14. Pancreatic ductal adenocarcinoma: time for a neoadjuvant revolution? Co-author DOI 10.1007/s13304-020-00798-3↗
  15. Reappraisal of nodal staging and study of lymph node station involvement in distal pancreatectomy for body-tail pancreatic ductal adenocarcinoma. First author DOI 10.1016/j.ejso.2020.04.006↗
  16. Respect - A multicenter retrospective study on preoperative chemotherapy in locally advanced and borderline resectable pancreatic cancer. Co-author DOI 10.1016/j.pan.2020.06.012↗
  17. Neoadjuvant therapy in elderly patients receiving FOLFIRINOX or gemcitabine/nab-paclitaxel for borderline resectable or locally advanced pancreatic cancer is f… Co-author DOI 10.1016/j.suronc.2020.08.031↗
  18. Does Site Matter? Impact of Tumor Location on Pathologic Characteristics, Recurrence, and Survival of Resected Pancreatic Ductal Adenocarcinoma. First author DOI 10.1245/s10434-020-08354-4↗
  19. The Sequential Radiographic Effects of Preoperative Chemotherapy and (Chemo)Radiation on Tumor Anatomy in Patients with Localized Pancreatic Cancer. Co-author DOI 10.1245/s10434-020-08427-4↗
  20. ASO Author Reflections: Does Site Matter? Impact of Tumor Location on Pathologic Characteristics, Recurrence, and Survival of Resected Pancreatic Ductal Adenoc… First author DOI 10.1245/s10434-020-08572-w↗
  21. Outcomes of Primary Chemotherapy for Borderline Resectable and Locally Advanced Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1001/jamasurg.2019.2277↗
  22. Evaluation of the MDACC clinical classification system for pancreatic cancer patients in an European multicenter cohort. Co-author DOI 10.1016/j.ejso.2018.12.012↗
  23. Core Set of Patient-reported Outcomes in Pancreatic Cancer (COPRAC): An International Delphi Study Among Patients and Health Care Providers. Co-author DOI 10.1097/sla.0000000000002633↗
  24. International Validation of the Eighth Edition of the American Joint Committee on Cancer (AJCC) TNM Staging System in Patients With Resected Pancreatic Cancer. Co-author DOI 10.1001/jamasurg.2018.3617↗
  25. Does the surgical waiting list affect pathological and survival outcome in resectable pancreatic ductal adenocarcinoma? Co-author DOI 10.1016/j.hpb.2017.10.017↗
  26. Screening/surveillance programs for pancreatic cancer in familial high-risk individuals: A systematic review and proportion meta-analysis of screening results. Co-author DOI 10.1016/j.pan.2018.04.002↗
  27. Neoadjuvant Therapy Versus Upfront Resection for Pancreatic Cancer: The Actual Spectrum and Clinical Burden of Postoperative Complications. Co-author DOI 10.1245/s10434-017-6281-9↗
  28. Recent Advances in Pancreatic Cancer Surgery. Co-author DOI 10.1007/s11938-017-0150-2↗
  29. Does Size Matter in Pancreatic Cancer?: Reappraisal of Tumour Dimension as a Predictor of Outcome Beyond the TNM. Co-author DOI 10.1097/sla.0000000000001837↗
  30. Downstaging in Stage IV Pancreatic Cancer: A New Population Eligible for Surgery? Co-author DOI 10.1245/s10434-017-5885-4↗
  31. Synchronous resections of hepatic oligometastatic pancreatic cancer: Disputing a principle in a time of safe pancreatic operations in a retrospective multicent… Co-author DOI 10.1016/j.surg.2016.02.019↗

Closest collaborators

The 25 strongest of 186 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Giuseppe Malleo · 28 shared papers, 2016–2026 · strength 3.10
  2. Roberto Salvia · 26 shared papers, 2017–2026 · strength 2.99
  3. Claudio Bassi · 22 shared papers, 2017–2023 · strength 2.27
  4. Salvatore Paiella · 12 shared papers, 2018–2023 · strength 1.36
  5. Aldo Scarpa Scarpa · 9 shared papers, 2017–2023 · strength 1.08
  6. Claudio Luchini · 8 shared papers, 2020–2023 · strength 1.06
  7. Giovanni Marchegiani · 10 shared papers, 2017–2022 · strength 0.88
  8. Gabriella Lionetto Lionetto · 5 shared papers, 2022–2026 · strength 0.83
  9. Michèle Milella · 5 shared papers, 2020–2023 · strength 0.62
  10. Massimo Falconi · 4 shared papers, 2020–2026 · strength 0.60
  11. Giulio Belfiori · 3 shared papers, 2023–2026 · strength 0.52
  12. Stefano Crippa · 3 shared papers, 2023–2026 · strength 0.52
  13. Erica Secchettin · 5 shared papers, 2018–2023 · strength 0.48
  14. Fabio Casciani · 4 shared papers, 2019–2024 · strength 0.46
  15. Cristina Rosa Ferrone · 4 shared papers, 2017–2023 · strength 0.44
  16. Alessandro Esposito · 4 shared papers, 2018–2023 · strength 0.43
  17. Paola Capelli · 4 shared papers, 2017–2022 · strength 0.43
  18. Carlos F. Fernandez-del Castillo · 3 shared papers, 2020–2022 · strength 0.40
  19. Alessandro Zerbi · 4 shared papers, 2016–2023 · strength 0.39
  20. Matteo De Pastena · 4 shared papers, 2018–2023 · strength 0.39
  21. Patrick Maisonneuve · 3 shared papers, 2020–2026 · strength 0.38
  22. Guralp Onur Ceyhan · 3 shared papers, 2020–2026 · strength 0.38
  23. Geert Kazemier M · 2 shared papers, 2024–2026 · strength 0.37
  24. Marta Sandini · 3 shared papers, 2018–2023 · strength 0.34
  25. Elena B. Rangelova · 2 shared papers, 2023–2026 · strength 0.34

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.